Pharmacogenomic considerations in the treatment of HIV infection

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Potent combination antiretroviral therapy (cART) has reduced human immunodeficiency virus (HIV)-related morbidity and mortality, and transformed HIV infection into a chronic condition requiring lifelong antiretroviral (ARV) therapy. Ensuring the safety and efficacy of ARV therapy (ART), including optimizing treatment via pharmacogenetic testing, is now a reality. Human leukocyte antigen (HLA)-B*5701 testing for the abacavir hypersensitivity reaction has become the standard of care and represents a classic example of successful pharmacogenetic testing to improve ARV treatment. Efavirenz and atazanavir are two additional ARV medications for which pharmacogenetic testing of cytochrome P450 (CYP)2B6 and uridine diphosphate glucuronosyltransferase (UGT)1A1, respectively, has shown promise. Pharmacogenomics of HIV infection, including feasibility and cost analysis, is an important area for continued research.

Original languageEnglish
Title of host publicationPharmacogenomics
Subtitle of host publicationChallenges and Opportunities in Therapeutic Implementation
PublisherElsevier
Pages227-245
Number of pages19
ISBN (Electronic)9780128126264
DOIs
Publication statusPublished - 01-01-2018

All Science Journal Classification (ASJC) codes

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'Pharmacogenomic considerations in the treatment of HIV infection'. Together they form a unique fingerprint.

Cite this